BRPI0419213A - Dry forms of aqueous solubilized bile acid dosage formulation: preparation and uses of these - Google Patents
Dry forms of aqueous solubilized bile acid dosage formulation: preparation and uses of theseInfo
- Publication number
- BRPI0419213A BRPI0419213A BRPI0419213-3A BRPI0419213A BRPI0419213A BR PI0419213 A BRPI0419213 A BR PI0419213A BR PI0419213 A BRPI0419213 A BR PI0419213A BR PI0419213 A BRPI0419213 A BR PI0419213A
- Authority
- BR
- Brazil
- Prior art keywords
- bile acid
- aqueous
- dry forms
- preparation
- dosage formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 6
- 239000003613 bile acid Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 3
- 229920002472 Starch Polymers 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000002244 precipitate Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 235000019698 starch Nutrition 0.000 abstract 2
- 239000008107 starch Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001412 amines Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000012084 conversion product Substances 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
FORMAS SECAS DE FORMULAçãO DE DOSAGEM DE AGIDO BILIAR SOLUBILIZADA AQUOSA: PREPARAçãO E USOS DESTAS. Composições para usos farmacêuticos e outros que compreendem soluções aquosas claras de ácidos biliares que não formam quaisquer precipitados detectáveis sobre as faixas selecionadas de valores de pH da solução aquosa e métodos de preparar tais soluções são descritas. Composições da descrição podem compreender água; um ácido biliar na forma de um ácido biliar, sal de ácido biliar ou ácido biliar conjugado com uma amina por uma ligação de amida; e qualquer um ou ambos os produtos de conversão de amido solúvel aquoso e um polissacarídeo de não amido solúvel aquoso. A composição permanece na solução sem formar um precipitado sobre uma faixa de todos os valores de pH obteníveis em um sistema aquoso. A composição, de acordo com algumas modalidades, pode também conter um composto farmacêutico em uma quantidade farmaceuticamente eficaz. A descrição também fornece formas secas de formulações de ácido biliar solubilizadas aquosas primárias e métodos de preparar tais formas secas.DRIED FORMS OF WATER SOLUBILIZED BILARY AGE DOSAGE FORMULATION: PREPARATION AND USE OF THESE. Pharmaceutical and other compositions comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over the selected pH range of the aqueous solution and methods of preparing such solutions are described. Compositions of the description may comprise water; a bile acid in the form of a bile acid, bile acid salt or bile acid conjugated to an amine by an amide bond; and either or both of the aqueous soluble starch conversion products and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of all pH values obtainable in an aqueous system. The composition, according to some embodiments, may also contain a pharmaceutical compound in a pharmaceutically effective amount. The description also provides dry forms of primary aqueous solubilized bile acid formulations and methods of preparing such dry forms.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2004/039507 WO2006057637A1 (en) | 2004-11-24 | 2004-11-24 | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0419213A true BRPI0419213A (en) | 2007-12-18 |
Family
ID=34959579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0419213-3A BRPI0419213A (en) | 2004-11-24 | 2004-11-24 | Dry forms of aqueous solubilized bile acid dosage formulation: preparation and uses of these |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1819318A1 (en) |
| JP (1) | JP2008521800A (en) |
| CN (1) | CN101065110A (en) |
| AU (1) | AU2004325203A1 (en) |
| BR (1) | BRPI0419213A (en) |
| CA (1) | CA2588168A1 (en) |
| WO (1) | WO2006057637A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772220B2 (en) | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US7145125B2 (en) | 2003-06-23 | 2006-12-05 | Advanced Optical Technologies, Llc | Integrating chamber cone light using LED sources |
| WO2006026555A2 (en) | 2004-08-30 | 2006-03-09 | Seo Hong Yoo | Neuroprotective effect of solubilized udca in focal ischemic model |
| DE602005027727D1 (en) | 2004-10-15 | 2011-06-09 | Seo Hong Yoo | COMPOSITIONS TO REDUCE THE TOXICITY OF CISPLATIN, CARBOPLATIN AND OXALIPLATIN |
| JP4778053B2 (en) | 2005-07-14 | 2011-09-21 | リセラ，インコーポレイテッド | Extended release lipolytic formulation for topical adipose tissue treatment |
| CA2744817C (en) | 2008-11-26 | 2020-07-07 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| JP2012509892A (en) | 2008-11-26 | 2012-04-26 | サティオゲン ファーマシューティカルズ，インク． | Compositions containing satiogens and methods of use |
| JP5420946B2 (en) * | 2009-03-23 | 2014-02-19 | 富士フイルム株式会社 | Minoxidil aqueous composition containing bile acids |
| US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| US20110152204A1 (en) * | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of Obesity or Diabetes with Bile Acid Sequestrants |
| EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| CN101843823B (en) * | 2010-05-27 | 2014-04-09 | 宫兆荣 | Anti-flu injection and preparation method thereof |
| US9597531B2 (en) | 2010-11-24 | 2017-03-21 | Neothetics, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
| CA2852957C (en) | 2011-10-28 | 2020-08-04 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| CN104023727B (en) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | Bile acid recycling inhibitors for the treatment of cholestatic liver disease in children |
| KR20180036580A (en) | 2016-09-30 | 2018-04-09 | 주식회사 유스바이오팜 | Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid |
| KR102252450B1 (en) * | 2017-02-09 | 2021-05-14 | 주식회사 아미코젠파마 | Composition for prevention or treatment of visual disorders comprising ursodeoxycholic acid |
| CN108272824A (en) * | 2018-03-11 | 2018-07-13 | 张显英 | A kind of bile extraction process |
| KR102297982B1 (en) * | 2019-09-27 | 2021-09-02 | 건양대학교 산학협력단 | A method for predicting using kits capable of predicting inhibition of rumen microorganism using bile acid |
| CN112138026A (en) * | 2020-10-28 | 2020-12-29 | 中南民族大学 | Application of bear gall powder in anti-intoxication and acute alcoholic fatty liver prevention medicines |
| AU2023366929A1 (en) | 2022-10-25 | 2025-05-08 | Veradermics, Incorporated | Compositions and methods of use for modified release minoxidil |
| CN115671408A (en) * | 2022-10-29 | 2023-02-03 | 金傅(北京)医疗科技有限公司 | Substance capable of avoiding granulation tissue hyperplasia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61171421A (en) * | 1985-08-23 | 1986-08-02 | Yamanouchi Pharmaceut Co Ltd | Production of stable prostaglandin e preparation |
| JPS62153220A (en) * | 1985-12-27 | 1987-07-08 | Tokyo Tanabe Co Ltd | Water-based bile acid agent for internal use |
| JPH0747539B2 (en) * | 1986-10-22 | 1995-05-24 | 東京田辺製薬株式会社 | Bile acid solid formulation |
| JPS63243031A (en) * | 1987-03-28 | 1988-10-07 | Tokyo Tanabe Co Ltd | Solid pharmaceutical of bile acid |
| JPH0624991A (en) * | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | Ursodesoxycholic acid depot |
| US5578304A (en) * | 1992-06-22 | 1996-11-26 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| IT1255968B (en) * | 1992-11-27 | 1995-11-17 | PHARMACEUTICAL COMPOSITIONS CONTAINING URSODESOXICOLIC ACID | |
| LU88375A1 (en) * | 1993-07-12 | 1994-04-01 | Michel Urso Prof Medecin Et Ch | Energy product stimulating male potency |
| EP1255566A2 (en) * | 2000-02-04 | 2002-11-13 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
-
2004
- 2004-11-24 CA CA002588168A patent/CA2588168A1/en not_active Abandoned
- 2004-11-24 WO PCT/US2004/039507 patent/WO2006057637A1/en not_active Ceased
- 2004-11-24 JP JP2007543006A patent/JP2008521800A/en active Pending
- 2004-11-24 AU AU2004325203A patent/AU2004325203A1/en not_active Abandoned
- 2004-11-24 CN CNA2004800444670A patent/CN101065110A/en active Pending
- 2004-11-24 BR BRPI0419213-3A patent/BRPI0419213A/en not_active IP Right Cessation
- 2004-11-24 EP EP04812094A patent/EP1819318A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006057637A1 (en) | 2006-06-01 |
| EP1819318A1 (en) | 2007-08-22 |
| CA2588168A1 (en) | 2006-06-01 |
| JP2008521800A (en) | 2008-06-26 |
| CN101065110A (en) | 2007-10-31 |
| AU2004325203A1 (en) | 2006-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0419213A (en) | Dry forms of aqueous solubilized bile acid dosage formulation: preparation and uses of these | |
| BR0108080A (en) | Preparation of aqueous clear bile acid solution dosage forms | |
| BR9912395A (en) | Preparation of dosage forms of clear aqueous solution with bile acids | |
| BRPI0513508A (en) | insulin-oligomer conjugates, formulations and uses of these | |
| BR112012004051A8 (en) | aqueous concentrate formulation, use of aqueous concentrate formulation and method to control unwanted vegetation | |
| DE602005025391D1 (en) | METHOD AND COMPOSITIONS FOR REDUCING NEURODE GENERATION IN AMYOTROPHIC LATERAL SCLEROSIS | |
| BRPI0611400B1 (en) | formulations containing mucus-adhesive xyloglycan useful in medical devices and pharmaceutical formulations | |
| CA2696335A1 (en) | Gel containing pirfenidone | |
| BR0113496A (en) | A compound or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, use thereof, method for producing a cell cycle inhibitory effect (anti-cell proliferation) in a warm-blooded animal, and pharmaceutical composition. | |
| BRPI0509592A (en) | flavored formulations containing sulfoalkyl ether sertraline and cyclodextrin | |
| BRPI0412291A (en) | nka / nk3 dual antagonists for the treatment of schizophrenia | |
| HRP20130071T1 (en) | Improved testosterone gel and method of use | |
| BR112019000849B1 (en) | LIQUID CLEANING COMPOSITIONS WITH ANTIBACTERIAL SYSTEM AND METHOD OF MANUFACTURING THEM | |
| BRPI0508933A (en) | compositions for topical delivery | |
| BR112015000088A8 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING RIFAMIXIN AND AMINO ACIDS AND THEIR PREPARATION PROCESSES | |
| UA93995C2 (en) | Pharmaceutical compositions for treating burns and process for the preparation thereof | |
| RU2006101686A (en) | COMPOSITIONS FOR LOCAL APPLICATION RESTORING THE STRUCTURE OF NAILS | |
| BR112015019776A2 (en) | dual-use oral tablets in sulfate salt pharmaceutical compositions and tablet use methods | |
| BRPI0411702B8 (en) | use of hyaluronic acid to prepare compositions for the treatment of thrush of the oral cavity | |
| HRP20140676T1 (en) | Formulations of deoxycholic acid and salts thereof | |
| US20220033743A1 (en) | Solid Cleansing Compositions with Taurine and Methods Thereof | |
| ITMI20071724A1 (en) | ANTIVIRAL TOPIC FORMULATIONS IN THE FORM OF BIOADESIVE GEL | |
| BRPI0412453A (en) | ascorbic acid or a physiologically acceptable salt thereof | |
| RU2018125252A (en) | Synergistic combination of pyrrolidone-carboxylic acid and / or its salts and hyaluronic acid and / or its salts for use in the treatment and / or prevention of dryness and irritation of mucous membranes | |
| ES2704694T3 (en) | Compositions comprising supramolecular complexes of polyanionic polymers and spermidine for use in the treatment of periodontium and damaged oral tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S) |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |